Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company is headquartered in Cambridge, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2019-10-03. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Follow-Up Questions
¿Quién es el CEO de Korro Bio Inc?
Dr. Ram Aiyar es el President de Korro Bio Inc, se unió a la empresa desde 2023.
¿Qué tal es el rendimiento del precio de la acción KRRO?
El precio actual de KRRO es de $42.25, ha increased un 0.23% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Korro Bio Inc?
Korro Bio Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Korro Bio Inc?
La capitalización bursátil actual de Korro Bio Inc es $396.7M
¿Es Korro Bio Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 10 analistas han realizado calificaciones de análisis para Korro Bio Inc, incluyendo 5 fuerte compra, 10 compra, 1 mantener, 0 venta, y 5 fuerte venta
